Dual PET/CT Imaging in Lung Cancer
Conditions
Lung Cancer
Conditions: official terms
Lung Neoplasms
Conditions: Keywords
Dual time PET/CT, glucose-6-phosphatase
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Intervention
Name: Dual FDG-PET/CT
Type: Other
Overall Status
Recruiting
Summary
The purpose of this study is to compare conventional PET/CT scan performed 1 hour after injection of the radioactive tracer FDG (PET/CT[1]) with PET/CT performed after 3 hours (PET/CT[3]) in a group of patients with biopsy verified lung cancer or high suspicion of lung cancer after initial work-up (chest x-ray and CT of thorax/upper abdomen), who are potentially operable.
Detailed Description
The investigators also want to:

- To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up (se Gold Standard 6.1.1)

- To compare SUVmax with the expression of GLUT1 and G-6-Pase in tumors

- To compare the expression of GLUT1 with the activity of G6Pase

- To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of relapse within a year after curative surgery
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Cytologic/histologic-verified lung cancer or high suspicion of lung cancer after initial work up

- Candidate to curative intended surgery after initial work up (usually chest x-ray, CT of chest/upper abdomen and if needed spirometry).

Exclusion Criteria:

- Former lung cancer

- Contraindications for PET/CT: Pregnancy, recent chemoradiotherapy

- Diabetes mellitus.
Location
Department of Pulmonary Medicine
Odense C, Fünen, Denmark
Status: Recruiting
Contact: Niels Christian Hansen, MD - niels.christian.hansen@rsyd.dk
Start Date
March 2012
Completion Date
March 2015
Sponsors
Odense University Hospital
Source
Odense University Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page